Health — TechQuire Post

Eli Lilly Sues Six Firms Over Alleged Black-Market Retatrutide Sales as Novo Nordisk CEO Pushes Back on 'Winner-Take-All' Framing

Eli Lilly on August 12 filed six lawsuits against U.S. firms it accuses of illegally selling black-market versions of its experimental obesity drug retatrutide. A day later, Novo Nordisk CEO Mike Doustdar said investors are underestimating demand for differentiated obesity drugs — pushing back against the market-share narrative that has driven Lilly's stock for two quarters.

TechQuire Daily Staff / 3 weeks, 2 days ago / 5 min read

FDA Approves BMS's Zenbexus, First CELMoD Therapy for Multiple Myeloma

The FDA granted accelerated approval on August 13 to Bristol Myers Squibb's iberdomide, sold as Zenbexus — the first cereblon E3 ligase modulation therapy for multiple myeloma and the first new drug cleared on an MRD endpoint.

TechQuire Daily Staff / 3 weeks, 6 days ago / 6 min read

FDA Grants Breakthrough Device Designation to Freenome's AI-Powered Lung Cancer Blood Test

The FDA on August 12, 2026 granted Breakthrough Device Designation to Freenome's SimpleScreen Lung, an AI/ML-powered multiomic blood test for adults 50 to 80 at high risk for lung cancer — the second major FDA milestone for the company in two months after its colorectal test was approved in late July.

TechQuire Daily Staff / 3 weeks, 6 days ago / 5 min read

FDA Clears PhenoNet to Begin Phase 3 Trial of Inhaled Alzheimer's Drug PHENOGENE-1A

PhenoNet announced August 13 that the FDA issued a May Proceed notice for its Phase 3 trial of PHENOGENE-1A, an inhaled formulation of cromolyn for early Alzheimer's disease, in both APOE4 and non-APOE4 patients.

TechQuire Daily Staff / 4 weeks ago / 5 min read

Taiho and Cullinan's Zipalertinib Meets Phase 3 Goal in First-Line Lung Cancer

Taiho and Cullinan Therapeutics' zipalertinib plus chemotherapy met the primary endpoint of the REZILIENT3 Phase 3 trial in first-line non-small cell lung cancer, teeing up a potential regulatory filing.

TechQuire Daily Staff / 4 weeks ago / 5 min read

Definium's LSD-Based Therapy Beats Analyst Expectations in Phase 3 Anxiety Trial

A single dose of DT120 cut generalized anxiety symptoms by 5.4 placebo-adjusted points (p<0.0001) in the 214-patient Voyage study — its second late-stage win this summer — with Jefferies modeling at least $1.5 billion in peak GAD sales.

TechQuire Daily Staff / 4 weeks, 1 day ago / 6 min read

AC Immune Wins FDA Fast Track for Parkinson's Vaccine-Style Therapy ACI-7104

The anti-alpha-synuclein active immunotherapy for early Parkinson's disease also cleared an IND allowing its Phase 2 VacSYn trial to expand to US sites, with full 100-week data expected in the second half of 2026.

TechQuire Daily Staff / 4 weeks, 2 days ago / 4 min read

Tenax Therapeutics Shares Plunge 85% After Phase 3 Heart Drug Misses Primary Endpoint

Tenax Therapeutics said its Phase 3 LEVEL study of TNX-103 failed to meet its primary endpoint, sending shares down more than 85% in pre-market trading on August 10, RTTNews reported, in the latest setback for the chronic heart failure field.

TechQuire Daily Staff / 1 month ago / 4 min read

MoonLake's Sonelokimab Hits Primary Endpoint in Phase 3 Psoriatic Arthritis Trial

The IZAR-1 trial met its week-16 primary endpoint with 42.1% of patients on the 60mg induction dose achieving ACR50, alongside strong skin and disease-activity secondary outcomes, and no new safety signals.

TechQuire Daily Staff / 1 month ago / 4 min read

FDA Approves Moderna's mFlusiva, the First mRNA Flu Shot

The FDA on August 5 approved mFlusiva, the first mRNA vaccine for seasonal flu, for adults 50 and older, after a late-stage trial of more than 40,000 people showed it was about 27% more effective than standard shots.

TechQuire Daily Staff / 1 month ago / 6 min read

Blackstone's AGS Health Files Updated Papers for $500 Million India IPO

Blackstone-backed healthcare revenue cycle management firm AGS Health filed updated draft papers for a $500 million initial public offering in India, Reuters reported on August 7, adding to a strong year for Indian healthcare listings.

TechQuire Daily Staff / 1 month ago / 6 min read

FDA Approves Twice-Rejected Oncolytic Virus Combination for Melanoma

The FDA granted accelerated approval on August 6 to vusolimogene oderparepvec-wtpg (Tudriqev) plus nivolumab for advanced melanoma that progressed on PD-1 therapy, after an advisory panel voted 10-3 in favor of the regimen.

TechQuire Daily Staff / 1 month ago / 6 min read

Largest-Ever Genetic Study Points to Nervous System Roots of Fibromyalgia

A landmark study of more than 2.5 million people identified 26 genetic risk loci for fibromyalgia and found the strongest evidence yet that it is a nervous system disorder rather than an autoimmune disease.

TechQuire Daily Staff / 1 month ago / 6 min read

Avoiding Smoking, Diabetes and High Blood Pressure in Midlife Tied to 13 More Dementia-Free Years

A study of 12,409 people followed for an average of 26 years found that three modifiable midlife risk factors — smoking, diabetes and hypertension — are linked to roughly 13 fewer years without dementia, NYU Langone and The Guardian report.

TechQuire Daily Staff / 1 month ago / 6 min read

FDA Approves Engineered Virus Therapy for Treatment-Resistant Melanoma

Tudriqev from Replimune — a herpes-virus-based injection given with nivolumab — shrank tumors in 24 percent of evaluable patients for a median 14.1 months, earning accelerated approval after an advisory panel voted 10-3.

TechQuire Daily Staff / 1 month ago / 6 min read

Study: UK Breast Screening Criteria Miss Most Under-50 Women Who Develop Cancer

Cambridge and ICR researchers say a Boadicea-based risk assessment would flag 26.5% of under-50 women for review and catch 34.8% of those who develop breast cancer within 10 years — versus 1.4% and 4.4% under current NICE rules.

TechQuire Daily Staff / 1 month ago / 6 min read

Psilocybin Therapy Shows Early Promise for Anorexia Recovery

A pilot study found that half of participants with long-standing anorexia nervosa had symptom scores comparable to people without a diagnosis three months after psilocybin-assisted therapy.

TechQuire Daily Staff / 1 month ago / 7 min read

AstraZeneca Shares Fall 8.9% as Merger Talks With US Cancer Drug Firm Bristol Emerge

A $400bn tie-up with Bristol Myers Squibb would create the world's fourth largest drugmaker, but analysts question the rationale for the deal, the Guardian reports.

TechQuire Daily Staff / 1 month ago / 5 min read

FDA Approves Novartis' Pluvicto for Earlier-Stage Prostate Cancer, Finishing Review a Month Early

The PSMA-targeted radioligand therapy won approval in combination with an androgen receptor pathway inhibitor for metastatic prostate cancer, based on a 28% reduction in progression or death in the Phase 3 PSMAddition trial.

TechQuire Daily Staff / 1 month, 1 week ago / 6 min read

Michigan Reports First Two U.S. Deaths in Outbreak of Cyclospora

Two people have died in the cyclospora outbreak in Michigan in the first confirmed deaths in the U.S. related to the microscopic parasite, state health officials announced.

TechQuire Daily Staff / 1 month, 1 week ago / 5 min read

BioNTech Names Guido Oelkers Its New CEO

Guido Oelkers will take over as the new CEO of BioNTech, replacing company cofounder Ugur Sahin, STAT reports.

TechQuire Daily Staff / 1 month, 1 week ago / 4 min read